Biotech Top Decliners: ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP), Intrexon Corporation (NYSE:XON), Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

On 6 August, Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) reported a loss of $39.4 million in its second quarter. On a per-share basis, the San Diego-based company said it had a loss of 39 cents. Losses, adjusted for stock option expense, came to 32 cents per share. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) belongs to Healthcare sector. Its weekly performance is -19.81%. On last trading day company shares ended up $39.14. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) distance from 50-day simple moving average (SMA50) is -10.95%.

BioCryst Pharmaceuticals, Inc., (NASDAQ:BCRX) announced that Robert A. Ingram was elected to the Company’s Board of Directors. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) shares decreased -23.62% in last trading session and ended the day at $10.90. BCRX Gross Margin is 100.00% and its return on assets is -36.80%. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) quarterly performance is 8.03%.

Vetr lowered shares of ZIOPHARM Oncology (NASDAQ:ZIOP) from a buy rating to a hold ratingin a research report report published onMonday, Analyst Ratings Network.com reports. The firm currently has $14.00 price target on the biotechnology company’s stock. On 07 August, ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) shares decreased -6.33% and was closed at $12.20. ZIOP EPS growth in last 5 year was 1.20%. ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) year to date (YTD) performance is 140.63%.

Intrexon Corporation (NYSE:XON) ended the last trading day at $59.51. Company weekly volatility is calculated as 7.25% and price to cash ratio as 35.82. Intrexon Corporation (NYSE:XON) showed a weekly performance of -8.80%.

On 6 August, it was reported Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) net loss according to accounting principles generally accepted in the U.S. (GAAP) for the second quarter of 2015 was $71.8 million, or $0.85 per share on both a basic and diluted basis (including $10.2 million, or $0.12 per share of non-cash stock-based compensation expense), as compared to a net loss of $44.1 million, or $0.58 per share on both a basic and diluted basis (including $7.7 million, or $0.10 per share of non-cash stock-based compensation expense), for the same period in the previous year. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) shares decreased -11.41% in last trading session and ended the day at $106.19. ALNY return on assets is -13.60%. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) quarterly performance is -5.85%.

Leave a Reply

Your email address will not be published. Required fields are marked *